NEUMORA THERAPEUTICS, INC. Financing Cash Flow
NEUMORA THERAPEUTICS, INC. (NMRA) reported Financing Cash Flow of $20.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $9.29M, a 49.67% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $10.88M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $58.77M, a 277.37% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$136.00K, a 108.88% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $77.09M, a 256.84% increase from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $21.60M, a 90.69% decline from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $231.94M, a 100.39% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $115.74M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $20.16M 10-Q · filed 2026-08-14 | $78.93M derived: sum of 3 quarters · filed 2026-08-14 | $78.80M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $10.88M 10-Q · filed 2026-05-07 | $69.64M derived: sum of 2 quarters · filed 2026-05-07 | $69.51M derived: sum of 3 quarters · filed 2026-05-07 | $87.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $58.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $58.63M derived: sum of 2 quarters · filed 2026-03-30 | $77.09M derived: sum of 3 quarters · filed 2026-08-14 | $77.09M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.32M derived: sum of 2 quarters · filed 2026-08-14 | $18.32M 10-Q · filed 2025-11-06 | $33.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $18.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $18.46M 10-Q · filed 2026-08-14 | $34.03M derived: sum of 3 quarters · filed 2026-08-14 | $35.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $15.57M derived: sum of 2 quarters · filed 2026-05-07 | $17.10M derived: sum of 3 quarters · filed 2026-05-07 | $19.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $17.10M derived: sum of 2 quarters · filed 2026-03-30 | $19.76M derived: sum of 3 quarters · filed 2026-03-30 | $21.60M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.18M derived: sum of 2 quarters · filed 2025-11-06 | $6.03M 10-Q · filed 2025-11-06 | $5.55M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.50M 10-Q · filed 2025-08-06 | $4.02M derived: sum of 3 quarters · filed 2025-08-06 | $236.04M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.84M 10-Q · filed 2025-05-12 | $1.36M derived: sum of 2 quarters · filed 2025-05-12 | $233.39M derived: sum of 3 quarters · filed 2025-05-12 | $233.68M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $231.54M derived: sum of 2 quarters · filed 2025-03-03 | $231.84M derived: sum of 3 quarters · filed 2025-03-03 | $231.94M 10-K · filed 2025-03-03 |
| 2023-09-30 | $232.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $232.32M derived: sum of 2 quarters · filed 2024-11-12 | $232.42M 10-Q · filed 2024-11-12 | $259.25M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $292.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $393.00K 10-Q · filed 2024-08-06 | $27.23M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $101.00K 10-Q · filed 2024-05-07 | $26.93M derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $26.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $115.74M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $88.91M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |